Get the Stockscreener App
31.18
1.40%
0.43
After Hours:
31.18
Supernus Pharmaceuticals Inc stock is traded at $31.18, with a volume of 340.57K.
It is up +1.40% in the last 24 hours and down -11.32% over the past month.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
See More
Previous Close:
$30.75
Open:
$30.82
24h Volume:
340.57K
Relative Volume:
0.73
Market Cap:
$1.73B
Revenue:
$597.40M
Net Income/Loss:
$-15.51M
P/E Ratio:
42.71
EPS:
0.73
Net Cash Flow:
$99.84M
1W Performance:
-0.76%
1M Performance:
-11.32%
6M Performance:
-8.59%
1Y Performance:
+13.09%
1-Day Range:
$30.82
$31.48
1-Week Range:
$29.74
$31.50
52-Week Range:
$21.99
$35.44
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
Name
Supernus Pharmaceuticals Inc
Sector
Phone
301-838-2500
Address
9715 KEY WEST AVENUE, ROCKVILLE, MD
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-03-23 | Resumed | Jefferies | Buy |
| Dec-01-21 | Resumed | Jefferies | Buy |
| Apr-13-21 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-15-20 | Resumed | Jefferies | Hold |
| Nov-08-19 | Downgrade | Berenberg | Buy → Hold |
| Nov-07-19 | Downgrade | Stifel | Buy → Hold |
| Nov-06-19 | Downgrade | Jefferies | Buy → Hold |
| Nov-12-18 | Reiterated | B. Riley FBR | Buy |
| Jan-18-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Dec-28-17 | Reiterated | B. Riley FBR, Inc. | Buy |
| Dec-04-17 | Upgrade | Janney | Neutral → Buy |
| Nov-08-17 | Upgrade | Stifel | Hold → Buy |
| Oct-19-17 | Initiated | FBR & Co. | Buy |
| Sep-19-17 | Downgrade | Stifel | Buy → Hold |
| Jul-17-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jul-14-17 | Initiated | Janney | Neutral |
| Jun-01-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jul-18-16 | Downgrade | Northland Capital | Outperform → Market Perform |
| Jul-18-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Feb-08-16 | Upgrade | Jefferies | Hold → Buy |
| Nov-05-15 | Reiterated | Northland Capital | Outperform |
| Oct-28-15 | Initiated | Northland Capital | Outperform |
View All
Supernus Pharmaceuticals Inc Stock (SUPN) Latest News
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Purchased by Dimensional Fund Advisors LP - MarketBeat
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Holdings Raised by Armistice Capital LLC - MarketBeat
Pulling back 3.6% this week, Supernus Pharmaceuticals' NASDAQ:SUPN) five-year decline in earnings may be coming into investors focus - Simply Wall St
Busy Philipps Encourages Women to Take Charge of Their ADHD - GlobeNewswire
Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree - StockTitan
Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue? - Yahoo Finance
Epoch Investment Partners Inc. Trims Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Super Micro's price target slashed at Loop Capital on margin issues (SMCI) - Seeking Alpha
When (SUPN) Moves Investors should Listen - Stock Traders Daily
Pacer Advisors Inc. Buys 1,348,508 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Mutual of America Capital Management LLC - MarketBeat
SUPN (Supernus Pharmaceuticals) Cash Ratio : 1.12 (As of Jun. 2024) - GuruFocus.com
Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit - StockTitan
Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit - GlobeNewswire
Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit - Yahoo Finance
Super Group (SGHC) Limited: Navigating a Turbulent Year, Up -9.39% from 52-Week Low - The InvestChronicle
Super Group (NYSE:SGHC) Sees Strong Trading Volume - MarketBeat
Drugmaker for rare disease soars 1,200% in last year - Kursiv Media
Superior Group (SGC) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
Super Micro poised for expansion as gross margin concerns ease and internal control risks priced in: analyst - The Bharat Express News
Super Micro Stock's Newest Bull Says It's 'The Coolest Kid in AI Town' - Investopedia
Needham initiates Buy on Super Micro shares, bullish on AI-driven growth opportunities - Investing.com Canada
Needham initiates coverage on Super Micro with Buy rating - Yahoo Finance
Super Micro Poised for Expansion as Gross Margin Concerns Ease, Internal Control Risks Priced In: Analyst - Benzinga
Market Highlights: Grupo Supervielle S.A. ADR (SUPV) Ends on a Low Note at 8.21 - The Dwinnex
Is Super Micro a value stock? This analyst thinks it could be. - MSN
Is Super Micro a value stock? This analyst thinks it could be. - MarketWatch
Renaissance Technologies LLC Has $45.08 Million Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Insider Sale at Supernus Pharmaceuticals Inc (SUPN) - GuruFocus.com
Supernus Pharmaceuticals Shows Improved Relative Price Performance; Still Shy Of Benchmark - Investor's Business Daily
SUPV’s price-to-sales ratio: Is it a good investment opportunity? - US Post News
Supernus Pharmaceuticals (SUPN) Slid on Disappointing Progress Report on a Key Drug - Insider Monkey
Supernus Pharmaceuticals (SUPN) Slid on Disappointing Progress Report on a Key Drug - Yahoo Finance
Bokf Na Purchases 20,093 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Ratio Revelations: Supernus Pharmaceuticals Inc (SUPN)’s Financial Metrics in the Spotlight - The Dwinnex
Victory Capital Management Inc. Raises Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Supernus cut to Neutral at Piper Sandler on Qelbree growth trajectory - MSN
Market Update: Supernus Pharmaceuticals Inc (SUPN) Sees Negative Movement, Closing at 31.08 - The Dwinnex
Supernus Pharmaceuticals (NASDAQ:SUPN) Downgraded to “Neutral” at Piper Sandler - Defense World
Natixis Advisors LLC Sells 3,676 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Supernus: Stock Slides As Qelbree Sales Questioned, But Positives Still Outweigh Negatives - Seeking Alpha
Supernus Pharmaceuticals (NASDAQ:SUPN) Shares Gap Down to $33.49 - MarketBeat
(SUPN) On The My Stocks Page - Stock Traders Daily
ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug - AOL
Supernus Pharmaceuticals Inc [SUPN] Stock bought by Insider TAMI TILLOTSON MARTIN for $0.12 million - Knox Daily
ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug - Benzinga
Supernus stock cut to Neutral at Piper Sandler (NASDAQ:SUPN) - Seeking Alpha
Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Rating Lowered by Piper Sandler - MarketBeat
Supernus stock downgraded to neutral, price target cut to $36 By Investing.com - Investing.com Canada
Candriam S.C.A. Takes Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Bank of New York Mellon Corp Has $11.38 Million Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Supernus Pharmaceuticals Inc Stock (SUPN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.23%
0.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):